Back to News
Market Impact: 0.2
Canaccord Genuity Initiates Coverage of Belite Bio, Inc - Depositary Receipt at Buy
Source: Nasdaq
Company FundamentalsAnalyst EstimatesAnalyst InsightsInvestor Sentiment & Positioning
Canaccord Genuity initiated coverage of Belite Bio (BLTE) on Sept. 4, 2026 with a Buy rating. The stock closed at $171.09 on Sept. 3 and then at $193.61 the following day (a +13.2% move), suggesting a positive market reaction to the initiation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BLTE0.50
More News
- Elon Musk says SpaceX and Tesla exploring largest merger in history
- Jio’s Record $3.2 Billion IPO Puts India’s Market Muscle to the Test
- Asia stocks rebound as SpaceX, Super Micro results lift chipmakers
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports